Phaseline

Companies › Iperboreal Pharma Srl

Iperboreal Pharma Srl: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Genitourinary, Cardiovascular; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XyloCore (Low, Medium, High Strength)
Peritoneal dialysis solution containing xylitol (0.7-2.0%), glucose (0.5-1.5%), and L-carn
–Phase 3End Stage Renal DiseaseDec 2026
PolyCore
Peritoneal ultrafiltration solution containing polydextrin, L-carnitine, and D-xylitol
–Phase 1Congestive Heart FailureDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03994874PolyCorePhase 1Congestive Heart FailureCardiovascularDec 2026
NCT03994471XyloCore (Low, Medium, High Strength)Phase 3End Stage Renal DiseaseGenitourinaryDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Rege Nephro Chengdu Suncadia Medicine Vaderis Therapeutics Addpharma Suzhou Alphamab

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.